• YouTube

1. Description of the different applications of the patent

García-Pérez J, Sánchez-Palomino S, Pérez-Olmeda M, Fernández B, Alcamí J. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1. J Med Virol. 2007 Feb;79(2):127-37.

García-Pérez J, Pérez-Olmeda M, Sánchez-Palomino S, Pérez-Romero P, Alcamí J. A new strategy based on recombinant viruses for assessing the replication capacity of HIV-1. HIV Med. 2008 Mar;9(3):160-71.

Pérez-Olmeda M, García-Pérez J, Mateos E, Spijkers S, Ayerbe MC, Carcas A, et al. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication. J Med Virol. 2009 Feb;81(2):211-6.

Fenyö EM, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, et al. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One. 2009;4(2):e4505.

González N, Pérez-Olmeda M, Mateos E, Cascajero A, Álvarez A, Spijkers S, et al. A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. J Antimicrob Chemother. 2010 Dec;65(12):2493-501.

Heyndrickx L, Heath A, Sheik-Khalil E, Alcamí J, Bongertz V, Jansson M, et al. International network for comparison of HIV neutralization assays: the NeutNet report II. PLoS One. 2012;7(5):e36438.

 2. Articles on neutralizing antibodies and vaccine trials

García F, Lejeune M, Climent N, Gil C, Alcamí J, Morente V, et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis. 2005 May 15;191(10):1680-5.

García F, Climent N, Assoumou L, Gil C, González N, Alcamí J, León A, Romeu J, Dalmau J, Martínez-Picado J, Lifson J, Autran B, Costagliola D, Clotet B, Gatell JM, Plana M, Gallart T; DCV2/MANON07- AIDS Vaccine Research Objective Study Group. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis. 2011 Feb 15;203(4):473-8.

Peña J, Frías M, Castro-Orgaz L, González R, García F, Gallart T, Gatell JM, Plana M; Dc2-Manon07 Vaccine Research Group. Effects on innate immunity of a therapeutic dendritic cell-based vaccine for HIV-1 infection. Viral Immunol. 2012 Feb;25(1):37-44.

García F, Bernaldo de Quirós JC, Gómez CE, Perdiguero B, Nájera JL, Jiménez V, et al. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine. 2011 Oct 26;29(46):8309-16.

Sánchez-Palomino S, Massanella M, Carrillo J, García A, García F, González N, et al. A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. Vaccine. 2011 Jul 18;29(32):5250-9.

 Medina-Ramírez M, Sánchez-Merino V, Sánchez-Palomino S, Merino-Mansilla A, Ferreira CB, Pérez I, et al. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia. J Virol. 2011 Jun;85(12):5804-13.

3. Articles on screening and analysis of antiviral compounds

Olmedo DA, López-Pérez JL, Del Olmo E, Bedoya LM, Sancho R, Alcamí J, et al. Neoflavonoids as Inhibitors of HIV-1 Replication by Targeting the Tat and NF-κB Pathways. Molecules. 2017;22(2).

Bedoya LM, Beltrán M, Obregón-Calderón P, García-Pérez J, de la Torre HE, González N, et al. Hydroxytyrosol: a new class of microbicide displaying broad anti-HIV-1 activity. AIDS. 2016 Nov 28;30(18):2767-2776.

Prado S, Beltrán M, Coiras M, Bedoya LM, Alcamí J, Gallego J. Bioavailable inhibitors of HIV-1 RNA biogenesis identified through a Rev-based screen. Biochem Pharmacol. 2016 May 1;107:14-28.

Callies O, Bedoya LM, Beltrán M, Muñoz A, Calderón PO, Osorio AA, et al. Isolation, Structural Modification, and HIV Inhibition of Pentacyclic Lupane-Type Triterpenoids from Cassine xylocarpa and Maytenus cuzcoina. J Nat Prod. 2015 May 22;78(5):1045-55.

Gianvincenzo PD, Calvo J, Perez S, Álvarez A, Bedoya LM, Alcamí J, et al. Negatively charged glyconanoparticles modulate and stabilize the secondary structures of a gp120 V3 loop peptide: toward fully synthetic HIV vaccine candidates. Bioconjug Chem. 2015 Apr 15;26(4):755-65.

González-Bulnes L, Ibáñez I, Bedoya LM, Beltrán M, Catalán S, Alcamí J, et al. Structure-based design of an RNA-binding p-terphenylene scaffold that inhibits HIV-1 Rev protein function. Angew Chem Int Ed Engl. 2013 Dec 9;52(50):13405-9.

Olmedo D, Sancho R, Bedoya LM, López-Pérez JL, Del Olmo E, Muñoz E, et al. 3-Phenylcoumarins as inhibitors of HIV-1 replication. Molecules. 2012 Aug 2;17(8):9245-57.

Osorio AA, Muñóz A, Torres-Romero D, Bedoya LM, Perestelo NR, Jiménez IA, et al. Olean-18-ene triterpenoids from Celastraceae species inhibit HIV replication targeting NF-kB and Sp1 dependent transcription. Eur J Med Chem. 2012 Jun;52:295-303.

García-Pérez J, Rueda P, Alcamí J, Rognan D, Arenzana-Seisdedos F, Lagane B, et al. Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5). J Biol Chem. 2011 Sep 23;286(38):33409-21.

López-Huertas MR, Mateos E, Díaz-Gil G, Gómez-Esquer F, Sánchez del Cojo M, Alcamí J, et al. Protein kinase Ctheta is a specific target for inhibition of the HIV type 1 replication in CD4+ T lymphocytes. J Biol Chem. 2011 Aug 5;286(31):27363-77.

García-Pérez J, Rueda P, Staropoli I, Kellenberger E, Alcamí J, Arenzana-Seisdedos F, et al. New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection. J Biol Chem. 2011 Feb 18;286(7):4978-90.

Bedoya LM, Abad MJ, Calonge E, Saavedra LA, Gutiérrez C M, Kouznetsov VV, et al. Quinoline-based compounds as modulators of HIV transcription through NF-kappaB and Sp1 inhibition. Antiviral Res. 2010 Sep;87(3):338-44.

Di Gianvincenzo P, Marradi M, Martínez-Ávila OM, Bedoya LM, Alcamí J, Penadés S. Gold nanoparticles capped with sulfate-ended ligands as anti-HIV agents. Bioorg Med Chem Lett. 2010 May 1;20(9):2718-21.

Bedoya LM, Abad MJ, Sánchez-Palomino S, Alcamí J, Bermejo P. Ellagitannins from Tuberaria lignosa as entry inhibitors of HIV. Phytomedicine. 2010 Jan;17(1):69-74.

Martínez-Ávila O, Bedoya LM, Marradi M, Clavel C, Alcamí J, Penadés S. Multivalent manno-glyconanoparticles inhibit DC-SIGN-mediated HIV-1 trans-infection of human T cells. Chembiochem. 2009 Jul 20;10(11):1806-9.

Bedoya LM, Márquez N, Martínez N, Gutiérrez-Eisman S, Álvarez A, Calzado MA, et al. SJ23B, a jatrophane diterpene activates classical PKCs and displays strong activity against HIV in vitro. Biochem Pharmacol. 2009 Mar 15;77(6):965-78.

Bedoya LM, Álvarez A, Bermejo M, González N, Beltrán M, Sánchez-Palomino S, et al. Guatemalan plants extracts as virucides against HIV-1 infection. Phytomedicine. 2008 Jun;15(6-7):520-4.

Bedoya LM, del Olmo E, Sancho R, Barboza B, Beltrán M, García-Cadenas AE, et al. Anti-HIV activity of stilbene-related heterocyclic compounds. Bioorg Med Chem Lett. 2006 Aug 1;16(15):4075-9.

Bedoya LM, Beltrán M, Sancho R, Olmedo DA, Sánchez-Palomino S, del Olmo E, et al. 4-Phenylcoumarins as HIV transcription inhibitors. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4447-50.

Márquez N, Sancho R, Bedoya LM, Alcamí J, López-Pérez JL, Feliciano AS, et al. Mesuol, a natural occurring 4-phenylcoumarin, inhibits HIV-1 replication by targeting the NF-kappaB pathway. Antiviral Res. 2005 Jun;66(2-3):137-45.

Sancho R, Medarde M, Sánchez-Palomino S, Madrigal BM, Alcamí J, Muñoz E, et al. Anti-HIV activity of some synthetic lignanolides and intermediates. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4483-6.

Sancho R, Márquez N, Gómez-Gonzalo M, Calzado MA, Bettoni G, Coiras MT, et al. Imperatorin inhibits HIV-1 replication through an Sp1-dependent pathway. J Biol Chem. 2004 Sep 3;279(36):37349-59.

Bermejo M, Sánchez-Palomino S, Usán L, Alcamí J. Dynamics of HIV replication in lymphocytes and the efficacy of protease inhibitors. J Med Virol. 2004 Aug;73(4):502-7.

Rullas J, Bermejo M, García-Pérez J, Beltán M, González N, Hezareh M, et al. Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes. Antivir Ther. 2004 Aug;9(4):545-54.




















Go to top

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site